Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatocellular Carcinoma: early-phase trial registry
65 of 146 indexed Hepatocellular Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #80 of 28,707 conditions by registered trial count.
146 US clinical trials · 65 currently recruiting · #80 of 28,707 conditions by registered trial count
Hepatocellular Carcinoma: 146 US clinical trials tracked, 65 recruiting.
Hepatocellular Carcinoma is the subject of 146 registered US clinical trials on ClinicalTrials.gov, 65 of them currently open to new participants. 20 are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 8 of these trials.
Enrollment posture brief
Registry condition hepatocellular-carcinoma
OPEN 65 | RECR 45% | LATE 20 | EARLY 92 | RANK #80 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Critical Illness (45% recruiting · 92 trials)
Hepatocellular Carcinoma lists 65 open slots (45% of 146 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatocellular Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatocellular Carcinoma is recruiting above its size-band peers.
65 of 146 indexed trials (44.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hepatocellular Carcinoma trials is spread across many organizations.
AstraZeneca accounts for 8 of 146 trials (5.5%). 94 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatocellular Carcinoma enrolment sits around 70 participants.
Median target enrolment is 70 among the 146 trials that report a genuine target (sentinel values excluded). 82 of those (56.2%) plan for fewer than 100 participants.
-
Hepatocellular Carcinoma research is mostly interventional.
129 interventional and 17 observational studies make up this index (88.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
146 total, page 3 of 3
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Memorial Sloan Kettering Cancer Center
NCT01840592
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Cancer Institute (NCI)
NCT03937830
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Jonsson Comprehensive Cancer Center
NCT04459273
Pressure-enabled Delivery in Radioembolization (TriNav Study)
Massachusetts General Hospital
NCT05128032
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Massachusetts General Hospital
NCT04857684
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
Abramson Cancer Center at Penn Medicine
NCT06204159
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
NCT02432963
BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors
SOTIO Biotech
NCT05120271
A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy
Bristol-Myers Squibb
NCT04161911
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
NCT02576509
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Imunon
NCT00617981
Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Imunon
NCT02112656
A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein
Eli Lilly and Company
NCT02435433
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
Daiichi Sankyo
NCT01755767
Prevention of Recurrent Hepatitis B After Liver Transplantation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00059267
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
University of Pittsburgh
NCT01640522
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
NCT01177397
Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
Pfizer
NCT01210495
EchoTip AcuCore Post-Market Clinical Study
Cook Research Incorporated
NCT06358001
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor
NCT03517488
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Sanofi
NCT05104567
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
H3 Biomedicine
NCT02834780
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)
University of Florida
NCT01203787
Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors
Kyowa Kirin
NCT02705105
Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
Thomas Jefferson University
NCT03199274
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma
Eisai
NCT01271504
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Eli Lilly and Company
NCT02572687
Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Icahn School of Medicine at Mount Sinai
NCT01871545
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Gilead Sciences
NCT01559844
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Incyte Corporation
NCT04580485
Assessment of Liver Cancer Response to TACE Using MultiHance-Enhanced MRI.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00539253
Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation
Baylor Research Institute
NCT02412579
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03652077
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Tempest Therapeutics
NCT03829436
Impact of Y90 Radiation Segmentectomy on HCC
Icahn School of Medicine at Mount Sinai
NCT03248375
RAD001 in Advanced Hepatocellular Carcinoma
Massachusetts General Hospital
NCT00516165
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
Northwestern University
NCT00846131
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT00802555
Identify Proteomic Biomarkers for Outcome Prediction of Locoregional Treatments for HCC
University of Texas Southwestern Medical Center
NCT04459468
STA-9090 in Patients With Advanced Hepatocellular Cancer
Massachusetts General Hospital
NCT01665937
A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy
Indiana University
NCT03338062
TRC105 for Liver Cancer That Has Not Responded to Sorafenib
National Cancer Institute (NCI)
NCT01375569
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
Emory University
NCT05250895
Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer
Polaris Group
NCT02101593
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
National Institutes of Health Clinical Center (CC)
NCT02471313
LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
University of Pittsburgh
NCT00877071
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 47 |
| Phase 2 | 45 |
| Phase 3 | 17 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatocellular Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatocellular Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatocellular Carcinoma page
146 registered trials, 65 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 65 Hepatocellular Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Hepatocellular Carcinoma trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatocellular Carcinoma condition card totals 146 registered trials; most-linked intervention Bevacizumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.